ACP: Ventricular fibrillation
ACP: Pulseless ventricular tachycardia
ACP: Unstable ventricular tachycardia
ACP: Recurrent ventricular tachycardia following cardioversion
ACP: ventricular fibrillation and pulseless ventricular tachycardia
ACP: unstable ventricular tachycardia and recurrent ventricular tachycardia following cardioversion
Safety and efficacy in children has not been established. Contact CliniCall if required.
Amiodarone is a Class III antiarrhythmic, but also possesses characteristics of all four Vaughn-Williams classes of medications. It blocks sodium channels in the heart, antagonizes beta adrenoreceptors to inhibit some sympathetic activity, produces negative chronotropic effects in nodal tissues, lengthens the cardiac action potential, and also slows conduction and prolongs refractoriness by blocking potassium channels.
Following intravenous administration:
Hypotension is the most commonly reported side effect following intravenous administration. In patients with a perfusing rhythm who are receiving amiodarone, if hypotension develops or worsens, slow the rate of the infusion. Nausea and bradycardia have also been reported.
QT interval prolongation has also been reported. QTc values greater than 500 ms may provoke Torsade de Pointes.
Accidental overdose of intravenous amiodarone is likely to produce hypotension, bradycardia, or cardiogenic shock. These should be managed by stopping or slowing the intravenous administration and providing volume replacement. Transcutaneous pacing may be required.
Amiodarone is toxic to tissues if extravasation occurs.
Amiodarone may enhance or potentiate the effects of beta blockers, calcium channel blockers, or digoxin and should be used with caution in these patients.